Long-term safety and efficacy of eculizumab in generalized myasthenia gravis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Muppidi_et_al-2019-Muscle_&_Nerve(1)
Forlagets udgivne version, 286 KB, PDF-dokument
INTRODUCTION: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy.
METHODS: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients.
RESULTS: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001).
DISCUSSION: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Muscle & Nerve |
Vol/bind | 60 |
Udgave nummer | 1 |
Sider (fra-til) | 14-24 |
Antal sider | 11 |
ISSN | 0148-639X |
DOI | |
Status | Udgivet - jul. 2019 |
Bibliografisk note
© 2019 The Authors. Muscle & Nerve published by Wiley Periodicals, Inc.
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 236273303